Utilizing its unique platform of cancer vaccines, Neogenix Oncology® has developed several monoclonal antibodies (“mAbs”). In 2008, the company began its first clinical study of a diagnostic biomarker, using several of its mAbs, to detect pancreatic and colon cancers. This study is ongoing and preliminary results have been presented at key scientific conferences.
Recently the company initiated a Phase 2a clinical trial of its lead therapeutic antibody candidate for advanced pancreatic and colorectal cancer. This multicenter trial is currently approved by the institutional review boards at The Johns Hopkins University Hospital, Duke University Medical Center.
The leading mAb candidate currently in product development—referred to as Ensituximab (or NPC-1C)—is one that recognizes a particular epitope of tumor specific antigens (“TSAs”) from pancreatic/colorectal adenocarcinoma. The Neogenix antibody is being developed as a therapeutic drug candidate for pancreatic and colorectal cancers and as part of a serum ELISA test for the detection of colon and pancreatic cancers.
Neogenix Oncology has two additional preclinical candidates, h16C3 and 31.1C. Both bind to tumor specific antigens found in pancreatic, colorectal and several other types of cancer.
With its proprietary library of cancer vaccines, antigens and antibodies, Neogenix Oncology is expanding its collaborations to identify further preclinical candidates that are tumor and disease specific.
“At the end of the day there's only one focus: to make a difference in the lives of patients affected by cancer.”
Philip M Arlen, MD
Chief Executive Officer